Duckie vs Aerska Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Duckie

EmergingInfrastructure

IT Operations

SF YC W24 AI support agent builder at 80% resolution time reduction and 71% ticket deflection; $500K from a16z/Greylock/YC/Netflix competing with Intercom Fin for customer support AI workflow automation.

AI VisibilityBeta
Overall Score
D25
Category Rank
#18 of 68
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
33
Perplexity
19
Gemini
36

About

Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 additional investors — providing customer support teams with an AI agent builder that translates existing support processes and workflows into predictable, reliable AI automation, achieving 80% reduction in resolution time and 71% ticket deflection for deployed teams. Founded in 2023 and targeting customer support leaders at growth-stage software companies, Duckie enables support teams to deploy AI agents in minutes without engineering dependency.

Full profile

Aerska Therapeutics

EmergingBioTech

CNS Gene Silencing (Alzheimer's / Parkinson's)

Raised $39M (Feb 2026, doubled from $21M Series A). Brain-shuttle + RNAi delivery for genetic Alzheimer's and Parkinson's. Non-viral CNS delivery crossing blood-brain barrier.

About

Aerska Therapeutics is developing a brain-shuttle RNAi (RNA interference) platform for CNS gene silencing — specifically targeting the genetic forms of Alzheimer's disease and Parkinson's disease caused by dominant mutations that can be silenced by RNA therapeutics. The company raised $39 million in February 2026, doubling its prior $21 million Series A round, led by ex-AstraZeneca neuroscience executives who validated both the science and the commercial opportunity.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.